Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.59% | 22.67% | -27.21% | 27.28% | 6.74% |
| Total Depreciation and Amortization | 35.32% | 85.59% | -19.36% | -4.35% | -3.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.22% | -48.90% | 91.12% | -13.03% | -42.33% |
| Change in Net Operating Assets | 1,767.26% | -98.77% | 240.04% | 180.52% | -142.19% |
| Cash from Operations | 19.72% | -61.55% | 29.61% | 48.34% | -14.46% |
| Capital Expenditure | 70.98% | 2.30% | -36.82% | -292.21% | -111.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.36% | 177.08% | 14,125.38% | -99.67% | 588.99% |
| Cash from Investing | -106.34% | 261.26% | 400.60% | -110.82% | 546.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 38.24% | 142.86% | -45.10% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 194.80% | 30.25% | -9.11% | -194.35% | 196.26% |
| Cash from Financing | -38.13% | 30.89% | -8.55% | -3.63% | 12.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.52% | 3,131.55% | 105.25% | -217.61% | 151.94% |